Gut microbiota and cardiovascular disease: opportunities and challenges
Open Access
- 14 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Microbiome
- Vol. 8 (1), 1-17
- https://doi.org/10.1186/s40168-020-00821-0
Abstract
Coronary artery disease (CAD) is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Over the past decade, it has become clear that the inhabitants of our gut, the gut microbiota, play a vital role in human metabolism, immunity, and reactions to diseases, including CAD. Although correlations have been shown between CAD and the gut microbiota, demonstration of potential causal relationships is much more complex and challenging. In this review, we will discuss the potential direct and indirect causal roots between gut microbiota and CAD development via microbial metabolites and interaction with the immune system. Uncovering the causal relationship of gut microbiota and CAD development can lead to novel microbiome-based preventative and therapeutic interventions. However, an interdisciplinary approach is required to shed light on gut bacterial-mediated mechanisms (e.g., using advanced nanomedicine technologies and incorporation of demographic factors such as age, sex, and ethnicity) to enable efficacious and high-precision preventative and therapeutic strategies for CAD.This publication has 262 references indexed in Scilit:
- Immunity, atherosclerosis and cardiovascular diseaseBMC Medicine, 2013
- TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid LoadingCell Metabolism, 2011
- Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatmentEMBO Molecular Medicine, 2011
- The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in miceHepatology, 2011
- Polymer‐based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisWIREs Nanomedicine and Nanobiotechnology, 2011
- Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43Nature, 2009
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expressionHepatology, 2008
- Probiotic modulation of symbiotic gut microbial–host metabolic interactions in a humanized microbiome mouse modelMolecular Systems Biology, 2008
- Human gut microbes associated with obesityNature, 2006
- Regulation of the mevalonate pathwayNature, 1990